Cargando…
Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK
Direct pharmacological targeting of the anti-apoptotic B-cell lymphoma-2 (BCL-2) family is an attractive therapeutic strategy for treating cancer. Obatoclax is a pan-BCL-2 family inhibitor currently in clinical development. Here we show that, although obatoclax can induce mitochondrial apoptosis dep...
Autores principales: | McCoy, F, Hurwitz, J, McTavish, N, Paul, I, Barnes, C, O'Hagan, B, Odrzywol, K, Murray, J, Longley, D, McKerr, G, Fennell, D A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032298/ https://www.ncbi.nlm.nih.gov/pubmed/21368880 http://dx.doi.org/10.1038/cddis.2010.86 |
Ejemplares similares
-
The great migration of Bax and Bak
por: Edlich, Frank
Publicado: (2015) -
Consequences of the combined loss of BOK and BAK or BOK and BAX
por: Ke, F, et al.
Publicado: (2013) -
Robust autoactivation for apoptosis by BAK but not BAX highlights BAK as an important therapeutic target
por: Iyer, Sweta, et al.
Publicado: (2020) -
Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer
por: Paul, I, et al.
Publicado: (2012) -
Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK
por: Ke, F, et al.
Publicado: (2015)